FMED – Fidelity Disruptive Medicine ETF
Fidelity Disruptive Medicine ETF (FMED) is a Health ETF, issued by Fidelity Investments, $65M in assets, 0.50% expense ratio.
Returns as of Oct 23, 2026: 1 week +4.1%, 1 year +7.7%.
Invests in disruptive medicine companies developing innovative ways to deliver products and services in healthcare.
Top holdings
- BSX – Boston Scientific Corp, 4.5%
- DHR – Danaher Corporation, 4.5%
- UCB – UCB SA, 3.9%
- ARGX – argenx NV ADR, 3.8%
- UMRX – Cogent Biosciences Inc, 3.7%
- VEEV – Veeva Systems Inc Class A, 3.4%
- ALNY – Alnylam Pharmaceuticals Inc, 3.4%
- PEN – Penumbra Inc, 3.3%
- PODD – Insulet Corporation, 2.8%
- ISRG – Intuitive Surgical Inc, 2.8%
- WAY – Waystar Holding Corp. Common Stock, 2.3%
- LFST – Lifestance Health Group Inc, 2.3%
- EW – Edwards Lifesciences Corp, 2.3%
- DIM – Sartorius Stedim Biotech SA, 2.1%
- INSM – Insmed Inc, 2.0%
- TMO – Thermo Fisher Scientific Inc, 2.0%
- MRNA – Moderna Inc, 2.0%
- LEGN – Legend Biotech Corp, 1.9%
- MASI – Masimo Corporation, 1.8%
- LLY – Eli Lilly and Company, 1.7%
- PCVX – Vaxcyte Inc, 1.7%
- CRNX – Crinetics Pharmaceuticals Inc, 1.6%
- SYK – Stryker Corporation, 1.6%
- PRVA – Privia Health Group Inc, 1.6%
- UNH – UnitedHealth Group Incorporated, 1.6%